245 related articles for article (PubMed ID: 29458119)
1. The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions.
Chen WT; Wang CW; Lu CW; Chen CB; Lee HE; Hung SI; Choon SE; Yang CH; Liu MT; Chen TJ; Fan WL; Su SC; Lin YY; Chang YC; Chung WH;
J Invest Dermatol; 2018 Jul; 138(7):1546-1554. PubMed ID: 29458119
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy.
Liu H; Wang Z; Bao F; Wang C; Sun L; Zhang H; Yu G; Mi Z; Li J; Li L; Zhao Q; Yue Z; Zhao W; Yu W; Cao J; Xiong F; Wang Y; Chai Z; Cheng X; Zhang Y; Fu F; Lang X; Wang X; Irwanto A; Krismawati H; Fu X; Sun Y; You J; Liu J; Pan Q; Chu T; Liu D; Chen S; Shen J; Yan L; Zhang G; Liu J; Zhang F; ; Xiong L; Yang J; Li J; Ke W; Li M; Ning Y; Xiong J; Li M; Xiong M; Yang B; Duan Q; Wang H; Li W; Kuang Y; Li J; Wang L; Cao Q; Xiao P; Xiao B; Zhang L; Lin Z; Wang Y; Shen Y; Yan L; Wu W; Zheng H; Zhan X; Li W; Shang X; Xu Y; Liu Q
JAMA Dermatol; 2019 Jun; 155(6):666-672. PubMed ID: 30916737
[TBL] [Abstract][Full Text] [Related]
3. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population.
Tempark T; Satapornpong P; Rerknimitr P; Nakkam N; Saksit N; Wattanakrai P; Jantararoungtong T; Koomdee N; Mahakkanukrauh A; Tassaneeyakul W; Suttisai S; Pratoomwun J; Klaewsongkram J; Rerkpattanapipat T; Sukasem C
Pharmacogenet Genomics; 2017 Dec; 27(12):429-437. PubMed ID: 28885988
[TBL] [Abstract][Full Text] [Related]
4. Association Between HLA-B*1301 and Dapsone-Induced Cutaneous Adverse Drug Reactions: A Systematic Review and Meta-analysis.
Tangamornsuksan W; Lohitnavy M
JAMA Dermatol; 2018 Apr; 154(4):441-446. PubMed ID: 29541744
[TBL] [Abstract][Full Text] [Related]
5. Validation study of HLA-B*13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia.
Krismawati H; Irwanto A; Pongtiku A; Irwan ID; Maladan Y; Sitanggang YA; Wahyuni T; Tanjung R; Sun Y; Liu H; Zhang F; Oktavian A; Liu J
PLoS Negl Trop Dis; 2020 Oct; 14(10):e0008746. PubMed ID: 33064728
[TBL] [Abstract][Full Text] [Related]
6. The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses.
Park HJ; Park JW; Kim SH; Choi SY; Kim HK; Jung CG; Yang MS; Kang DY; Cho MK; Kwon HS; Kang HR; Lee YW;
Expert Opin Drug Saf; 2020 Oct; 19(10):1349-1356. PubMed ID: 32700588
[TBL] [Abstract][Full Text] [Related]
7.
Satapornpong P; Pratoomwun J; Rerknimitr P; Klaewsongkram J; Nakkam N; Rungrotmongkol T; Konyoung P; Saksit N; Mahakkanukrauh A; Amornpinyo W; Khunarkornsiri U; Tempark T; Wantavornprasert K; Jinda P; Koomdee N; Jantararoungtong T; Rerkpattanapipat T; Wang CW; Naisbitt D; Tassaneeyakul W; Ariyachaipanich M; Roonghiranwat T; Pirmohamed M; Chung WH; Sukasem C
Front Immunol; 2021; 12():661135. PubMed ID: 34017337
[No Abstract] [Full Text] [Related]
8. A Review on Dapsone Hypersensitivity Syndrome Among Chinese Patients with an Emphasis on Preventing Adverse Drug Reactions with Genetic Testing.
Wang N; Parimi L; Liu H; Zhang F
Am J Trop Med Hyg; 2017 May; 96(5):1014-1018. PubMed ID: 28167593
[TBL] [Abstract][Full Text] [Related]
9. HLA-B*13:01 and the dapsone hypersensitivity syndrome.
Zhang FR; Liu H; Irwanto A; Fu XA; Li Y; Yu GQ; Yu YX; Chen MF; Low HQ; Li JH; Bao FF; Foo JN; Bei JX; Jia XM; Liu J; Liany H; Wang N; Niu GY; Wang ZZ; Shi BQ; Tian HQ; Liu HX; Ma SS; Zhou Y; You JB; Yang Q; Wang C; Chu TS; Liu DC; Yu XL; Sun YH; Ning Y; Wei ZH; Chen SL; Chen XC; Zhang ZX; Liu YX; Pulit SL; Wu WB; Zheng ZY; Yang RD; Long H; Liu ZS; Wang JQ; Li M; Zhang LH; Wang H; Wang LM; Xiao P; Li JL; Huang ZM; Huang JX; Li Z; Liu J; Xiong L; Yang J; Wang XD; Yu DB; Lu XM; Zhou GZ; Yan LB; Shen JP; Zhang GC; Zeng YX; de Bakker PI; Chen SM; Liu JJ
N Engl J Med; 2013 Oct; 369(17):1620-8. PubMed ID: 24152261
[TBL] [Abstract][Full Text] [Related]
10. A docking model of dapsone bound to HLA-B*13:01 explains the risk of dapsone hypersensitivity syndrome.
Watanabe H; Watanabe Y; Tashiro Y; Mushiroda T; Ozeki T; Hashizume H; Sueki H; Yamamoto T; Utsunomiya-Tate N; Gouda H; Kusakabe Y
J Dermatol Sci; 2017 Dec; 88(3):320-329. PubMed ID: 28870516
[TBL] [Abstract][Full Text] [Related]
11. Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients.
Sukasem C; Chaichan C; Nakkrut T; Satapornpong P; Jaruthamsophon K; Jantararoungtong T; Koomdee N; Sririttha S; Medhasi S; Oo-Puthinan S; Rerkpattanapipat T; Klaewsongkram J; Rerknimitr P; Tuchinda P; Chularojanamontri L; Tovanabutra N; Puangpetch A; Aekplakorn W
J Immunol Res; 2018; 2018():2780272. PubMed ID: 29546073
[TBL] [Abstract][Full Text] [Related]
12. Association between HLA-B*1301 and dapsone-induced hypersensitivity reactions among leprosy patients in China.
Wang H; Yan L; Zhang G; Chen X; Yang J; Li M; Shen J; Yu M; Huo R; Wang B
J Invest Dermatol; 2013 Nov; 133(11):2642-2644. PubMed ID: 23604100
[No Abstract] [Full Text] [Related]
13. T-cell plasticity of dapsone and DRESS.
Markova A; Duquesnoy R; Levis W
J Drugs Dermatol; 2014 Jan; 13(1):12-3. PubMed ID: 24385113
[No Abstract] [Full Text] [Related]
14. Granulysin-Based Lymphocyte Activation Test for Evaluating Drug Causality in Antiepileptics-Induced Severe Cutaneous Adverse Reactions.
Chu MT; Wang CW; Chang WC; Chen CB; Chung WH; Hung SI
J Invest Dermatol; 2021 Jun; 141(6):1461-1472.e10. PubMed ID: 33340500
[TBL] [Abstract][Full Text] [Related]
15. Fatal dapsone hypersensitivity syndrome with hypothyroidism and steroid-induced diabetes mellitus.
Pai S; Munshi R; Nayak C
Indian J Pharmacol; 2017; 49(5):396-398. PubMed ID: 29515281
[TBL] [Abstract][Full Text] [Related]
16. Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population.
Chang CC; Ng CC; Too CL; Choon SE; Lee CK; Chung WH; Hussein SH; Lim KS; Murad S
Pharmacogenomics J; 2017 Mar; 17(2):170-173. PubMed ID: 26927288
[TBL] [Abstract][Full Text] [Related]
17. Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions.
Ng CY; Yeh YT; Wang CW; Hung SI; Yang CH; Chang YC; Chang WC; Lin YJ; Chang CJ; Su SC; Fan WL; Chen DY; Wu YJ; Tian YC; Hui RC; Chung WH;
J Invest Dermatol; 2016 Jul; 136(7):1373-1381. PubMed ID: 26996548
[TBL] [Abstract][Full Text] [Related]
18. Characterization of T-Cell Responses to SMX and SMX-NO in Co-Trimoxazole Hypersensitivity Patients Expressing
Pratoomwun J; Thomson P; Jaruthamsophon K; Tiyasirichokchai R; Jinda P; Rerkpattanapipat T; Tassaneeyakul W; Nakkam N; Rerknimitr P; Klaewsongkram J; Srinoulprasert Y; Pirmohamed M; Naisbitt DJ; Sukasem C
Front Immunol; 2021; 12():658593. PubMed ID: 33995375
[No Abstract] [Full Text] [Related]
19. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin.
Chung WH; Chang WC; Stocker SL; Juo CG; Graham GG; Lee MH; Williams KM; Tian YC; Juan KC; Jan Wu YJ; Yang CH; Chang CJ; Lin YJ; Day RO; Hung SI
Ann Rheum Dis; 2015 Dec; 74(12):2157-64. PubMed ID: 25115449
[TBL] [Abstract][Full Text] [Related]
20. Dapsone: An Update.
Karjigi S; Murthy SC; Kallappa H; Kusuma MR; Aruna B; Reddy YN
Indian J Lepr; 2016 Sep; 87(4):233-239. PubMed ID: 29762952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
